U.S. Food and Drug Administration Sr Financial Analyst Salaries in Wilmington, DE
The average U.S. Food and Drug Administration Sr Financial Analyst in Wilmington, DE earns an estimated $70,504 annually, which includes an estimated base salary of $65,904 with a $4,600 bonus. U.S. Food and Drug Administration's Sr Financial Analyst compensation is $16,906 less than the US average for a Sr Financial Analyst. Sr Financial Analyst salaries at U.S. Food and Drug Administration in Wilmington, DE can range from $66,000 - $75,000.
In Wilmington, DE, The Finance Department at U.S. Food and Drug Administration earns $14,133 more on average than the Admin Department.
Last updated 3 years ago.
- $65,904
- avg. base
- $4,600
- avg. bonus
Sr Financial Analyst Salaries at U.S. Food and Drug Administration
In Wilmington, DE, Sr Financial Analysts earn $1,604 more than Financial Analysts, and $22,042 less than Senior Accountants.
Compensation at U.S. Food and Drug Administration by Department
In Wilmington, DE, The Finance Department averages $14,133 more than the Admin Department, and $10,567 less than the IT Department
Sr Financial Analyst Compensation by Gender (All Companies)
The average female Sr Financial Analyst at companies similar size to U.S. Food and Drug Administration reported making $93,556, while the average male Sr Financial Analyst at similar sized companies reported making $91,853.
Sr Financial Analyst Compensation by Ethnicity (All Companies)
The average Asian or Pacific Islander Sr Financial Analyst at companies similar size to U.S. Food and Drug Administration reported making $98,729, while the average Native American Sr Financial Analyst at similar sized companies reported making $60,000.
How Sr Financial Analysts at U.S. Food and Drug Administration Rate Their Compensation
The majority of Sr Financial Analysts at U.S. Food and Drug Administration believe they're compensated fairly. 100% of Sr Financial Analysts at U.S. Food and Drug Administration say they receive annual bonuses, and the vast majority (71%) are satisfied with their benefits. See more compensation ratings at U.S. Food and Drug Administration
